Figure 2.
Performance on geriatric assessment predicts survival, nonhematologic adverse events, and treatment discontinuation in multiple myeloma (n = 869). Reprinted with permission.39
Performance on geriatric assessment predicts survival, nonhematologic adverse events, and treatment discontinuation in multiple myeloma (n = 869). Reprinted with permission.39
